| | | Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board
PLOTSKER BRINGS PHARMA, BREAST CANCER EXPERTISE TO PROVECTUS
KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Biopharmaceuticals, Inc. (PVCT) ( http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has appointed Jacob M. Plotsker to its strategic advisory board.
Mr. Plotsker, age 46, is currently Director of IUS Strategy and Lifecycle Management at Bayer Healthcare. Jacob started his career as a staff accountant at Deloitte & Touche. He started his career in the pharmaceutical industry in 1990 when he joined Pfizer, where over the next 16 years he held roles of increasing responsibility in the Finance and Marketing functions. He subsequently moved to Organon BioSciences/Schering Plough as Senior Director of US and Global Marketing. From 2009 to 2012, he worked for Teva Pharmaceuticals as Head of Marketing and Senior Director, Commercial Operations in the branded Womens Health Division.
Mr. Plotsker currently serves on the board of directors of Emisphere Technologies, a publicly traded drug delivery technology company. From 2008 to 2014, he served on the board of directors of Sharsheret, a national 501(c)(3) not-for-profit organization providing support and resources to young women living with breast cancer. He served as President of Sharsheret from 2009-2012.
He holds a BA from Queens College of the City University of New York, an MBA from the Stern School of Business at New York University, and completed the Executive Program in General Management at the University of Chicago's Booth School of Business.
Dr. Craig Dees, PhD, CEO of Provectus said, "We are very happy that Jacob is joining the Provectus Strategic Advisory Board. He is a seasoned executive with extensive experience in US and international marketing, product launches and commercial operations in the pharmaceutical industry. Provectus will benefit greatly from all of these talents and abilities as we work to bring PV-10 and other preparations to the marketplace.
Mr. Plotsker said, I am excited at becoming a member of the Provectus Strategic Advisory Board. The Company is at a very important juncture in its development. PV-10's pending application for breakthrough therapy designation is an important milestone for the product and the Company. As the Company continues to advance the development of PV-10, the preparation for commercialization will take on an increasingly important role. I look forward to leveraging my experience to benefit patients in need of new therapies and contributing to Provectus™ future success. |
|
